{
    "nct_id": "NCT03856359",
    "official_title": "Pilot, Single Center, Open, Trial of Rifaximin in Probable Alzheimer's Disease",
    "inclusion_criteria": "* Â· Probable Alzheimer's Disease (National Institute of Neurological Disorders and Stroke (NINDS) criteria), mild to moderate severity\n\n  * Ages 55-85; both genders\n  * Mini Mental State Exam (MMSE) scores 10-23\n  * Willing and able to comply with all scheduled clinic visits.\n  * Stable medical health\n  * Has a family or professional caregiver who has regular contact with subject\n  * Ability to consent or legal guardian who can consent\n  * Living at home or in a facility\n  * On no AD therapies or on stable (2 months) concurrent AD therapies\nHealthy volunteers allowed\nMust have minimum age of 55 Years\nMust have maximum age of 85 Years",
    "exclusion_criteria": "* Past history of C diff infection\n* Assessment, laboratory examination, physical examination or any other medical condition or circumstance making the volunteer unsuitable for participation in the study in the judgment of the study clinicians\n* Allergy to Rifaximin\n* Antibiotic use or hospitalization in the last 6 months\n* Are taking medications that interact with rifaximin and/or pose a safety risk in the judgment of the PI\n* Clinically significant abnormal hepatic or renal function\n* Uncorrected thyroid or B12 abnormalities\n* Participation in another investigational drug trial in the past 30 days\n* History of febrile illness within 5 days prior to the study period\n* Known Hyperammonemia caused by:\n\nValproic acid Chemotherapy Lung transplant Bariatric surgery Ureterosigmoidoscopy Hyperalimentation Urinary tract infection Errors of metabolism: urea cycle, enzyme deficiencies, organic acidemias, fatty acid oxidation, amino acid transport defects",
    "miscellaneous_criteria": ""
}